GVK BIO Newsletter, Feb-2012

GVK BIO co-hosts BioAsia 2012


The life-sciences capital of India, Hyderabad, was host to India's premier global bio business forum. Attending this were more than 250 companies and delegations from Sri Lanka, Korea, Iran, Germany, Belgium, Pennsylvania, Singapore, Egypt, Africa, Thailand, Nepal among others. Business leaders, regulators, bureaucrats, policy makers, venture capitalists, bankers, scientists and students were present. BioAsia offered a good platform to share, hear, participate, discuss and identify partners. This year's theme of "Optimizing Opportunities" had a 4-fold focus on vaccines, CROs, investments and IPRs. Manni Kantipudi, CEO, GVK BIO was on the organizing committee for the forum and a panelist on the session "Contract Research market - growth opportunities".

BioAsia2012 - GVK BIO's Booth

LinkedIn LinkedIn Twitter Share This

GVK BIO wins Frost and Sullivan award for Growth Leadership in Contract Research Market

Frost and SullivanThe prestigious Frost & Sullivan 2011 Best Practices Award for Growth Leadership in the Contract Research Services Market was awarded to GVK BIO for accomplishments in the contract research market. This award is presented for excellence in capturing an impressive growth rate after being measured for their growth, leadership position, new service lines and process improvements. Our flexibility to change with client priorities and our constant endeavor to beat benchmarks clinched us this award.

LinkedIn LinkedIn Twitter Share This


Drug Discovery Collaboration with Moulder Center for Drug Discovery Research

Temple UniversityGVK BIO has entered into a multi-year drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University. We will be jointly responsible for designing the molecules, optimizing and progressing them through lead optimization to a pre-clinical candidate. We will perform target validation, lead identification and optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders. Applying our integrated drug discovery expertise and technologies, we'll help identify interesting small molecules against selected targets. We will also be responsible for reagent generation, assay development and establishment of screening cascade, leading to lead identification and optimization.

The Moulder Center is a unique, fully integrated state-of-the-art drug discovery center, used for both internal research and for collaborations with pharma and biotech companies and other universities.

LinkedIn LinkedIn Twitter Share This


In this issue

Share this!

LinkedIn LinkedIn Twitter Share This


Know someone who might be interested in this email? If you do, please forward this e-mail message to them.

More Information

For further information please contact: info@gvkbio.com


To unsubscribe please write to info@gvkbio.com


Proof Centre of ExcellencePartnership with PROOF Centre of Excellence, University of British Columbia for Biomarker development and Commercialization

GVK BIO's partnership with PROOF focuses on biomarker development for heart, lung and kidney failure. The PROOF (Prevention of Organ Failure) Centre is a not-for-profit Centre of Excellence for Commercialization and Research funded by the Government of Canada. The Centre licensed the popular GVK BIO Online Clinical Biomarker Database (GOBIOM) to help evaluate the commercialization potential of its biomarkers for heart, lung and kidney disease.

LinkedIn LinkedIn Twitter Share This



SAR Database in demand

Astellas Pharma extended and renewed its license for the GOSTAR - the GVK BIO SAR (Structure Activity Relationship) Databases. GOSTAR is our online scientific database which integrates information on compounds from discovery & development stages with marketed drugs. Information provided includes SAR, ADME, toxicity, preclinical, clinical and structural data for over 5.1 million compounds and 16.7 million SAR points. If you would like to access GVK BIO's unique GOSTAR (SAR database) or the GOBIOM (Biomarker database), please write to bdinf@gvkbio.com or visit https://gostardb.com/gostar/ or https://gobiomdb.com/gobiom/

LinkedIn LinkedIn Twitter Share This


Clinical Pharmacology unit comes out successfully with first UK MHRA inspection

mhraGVK BIO's Clinical Pharmacology unit was inspected by UK MHRA for the first time. The audit was conducted from Oct 10th-14th, 2011 by 3 inspectors, including one from the Ministry of Health, The Netherlands. There were no critical or major observations as per the auditor's reports. Our Clinical Pharmacology divisions at Ahmedabad and Hyderabad have an excellent regulatory track record, inspected and approved by agencies such as DCGI, USFDA, ANVISA-Brazil, AFSSAPS (France), MoH Turkey and WHO. Till date, the studies conducted for Europe submissions at the Clinical Pharmacology unit stand at approximately 75. The USFDA approved 53 studies, a clear testimony to our quality.

LinkedIn LinkedIn Twitter Share This

New Chemistry Capabilities
Chemistry Capabilities

We strengthened our chemistry services portfolio by adding new and specialized offerings to accelerate the client's drug discovery process. The new service lines include isotope labeling services, electronic chemistry, agrochemicals, in-house building blocks, on-shelf compounds, peptides & peptidomimetics, carbohydrates, nucleosides and virtual libraries and building blocks. We have deployed a core team of scientists with extensive experience and expertise and have equipped them with cutting edge infrastructure and technology. Thus enabling them to undertake complex research projects suited to each client's needs, be it a short-term project, a long-term collaboration, a library, mg to kg, or specialty chemistry. For further queries please write to mailto:bdmcl@gvkbio.com

LinkedIn LinkedIn Twitter Share This


Dr Lavleen Kumar Gupta joins as Vice President, Biology Services

Dr. GuptaTo meet the increasing business demands and further strengthen our scientific expertise, we recently appointed Dr Lavleen Kumar Gupta as Vice President and Head of Biology Services. He has over 20 years of research experience in discovery, preclinical and clinical research with leading pharma and biopharma companies. He has worked for Torrent Research Centre, Cadila Pharmaceuticals, Ranbaxy Research Laboratories and Lupin Research Park. He also held senior level positions at Chembiotek Research International and Lilly-Singapore Centre for Drug Discovery PTE Ltd, Singapore. He was last associated as Research Advisor (Biology) to Curadev Pharma Pvt Ltd. Dr Lavleen Gupta is a Ph. D. in Microbiology & Immunology and M.V.Sc. (MD) Immunology from Indian Veterinary Research Institute. He also has several scientific publications to his credit.

LinkedIn LinkedIn Twitter Share This


Frank ColeGVK BIO appoints Mr Frank J Cole as Director -
Sales & Marketing, Informatics

Mr Frank J Cole comes with over 15 years of experience and has been associated with Cambridge Soft, Accelrys/Scitegic Inc., MDL and Dendrite International, He will be based in Pennsylvania, USA. Mr Cole has an MBA in Marketing/Management from Wilkes University. For any Informatics Services or Products related queries, please contact frank.cole@gvkbio.com

LinkedIn LinkedIn Twitter Share This


Dr Mahesh Lachyankar joins as Director - Business Development, Biology Services

Dr Mahesh LachyankarRecently appointed, Dr Mahesh Lachyankar, will be based in Massachusetts, USA. He comes to GVK BIO with over 15 years of experience and was earlier associated with Pfizer Inc, as Director and Site Lead External Research Solutions (ERS). Prior to which, he was with Abbott Laboratories, Worcester MA. Mahesh was awarded his Ph. D. in Applied Biology from Bombay University, Mumbai and Post-Doctoral Research work from Worcester Foundation for Biomedical Sciences (WFBR), Shrewsbury, Massachusetts. He has several scientific publications in international journals and patents to his credit. For deals, partnerships and services relating to Biology, please contact mahesh.lachyankar@gvkbio.com

LinkedIn LinkedIn Twitter Share This


Waters XEVO TQ-S LC-MS/MS commissioned at Clinical Pharmacology, Hyderabad

WatersThe Clinical Pharmacology Unit at Hyderabad added a new hi-tech instrument - Waters XEVO TQ-S LC-MS/MS, expanding capabilities to serve customers. XEVO TQ-S plays a key role in quantification of pharmaceuticals in biological fluids to support drug development and discovery. High sensitivity performance facilitates lower levels of sensitivity, allowing researchers to measure drugs at even lower dose levels or with reduced sample volumes. This becomes applicable when using genetically-engineered rodents or in dried blood spot bioanalysis. For all bioanalytical, bioequivalence-of-special-population studies, please write to mailto:bdcpu@gvkbio.com

LinkedIn LinkedIn Twitter Share This


GVK Biosciences Private Limited
#28 A, IDA Nacharam
Hyderabad 500 076, India
T: 91 40 66929999
F: 91 40 66929900
W: http://www.gvkbio.com/?src=0811newsletter

Chemistry Services



Clinical Research

Clinical Pharmacology

Process R&D